Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Submission based on results from pivotal phase III trial showing all primary endpoints met
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated
